Biologielaborant Jobs in Solingen

For 75 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Für die Abteilung Virologie am Standort Erkrath suchen wir ab sofort unbefristet in Vollzeit eine / n

Biologisch-Technischen Assistenten (BTA)  /

Biologielaboranten / B.Sc. Biologie-Biotechnologie

als Technical Officer (m / w / d)

Zu Deinen Aufgaben zählen :

• Laborarbeiten mit Zellkulturen, Mykoplasmen und Viren
• der Nachweis von Viren und Mykoplasmen in biologischen Probenmaterialien
• selbständige Durchführung und Dokumentation bioanalytischer Methoden
• Erstellung von prüfungsbezogenen und übergreifenden Dokumenten
• allgemeine Laborarbeiten, z.B. Gerätewartungen
• Arbeiten und Dokumentation unter GMP-Bedingungen
• Pflege und Aufrechterhaltung des GMP-Systems
• Erstellen von Standardarbeitsanweisungen

Das bringst Du mit :

Wir bieten Dir :

Haben wir Dein Interesse geweckt?

Wenn ja, bewirb Dich bitte unter der Job-ID 223590  über unser Karriereportal mit Deinen aussagekräftigen Bewerbungsunterlagen, Deinem frühestmöglichen Eintrittstermin sowie Deinen Gehaltsvorstellungen.

Wir freuen uns auf Deine Bewerbung!

Charles River Laboratories Germany GmbH

Human Resources

Max-Planck-Str. 15a

40699 Erkrath

Bei Fragen bitte an wenden

About Biologics Testing Solutions

With more than 50 years of experience and proven regulatory expertise, the Charles River Biologics group can address challenging projects for biotechnology and pharmaceutical companies worldwide. Offering a variety of services such as contamination and impurity testing, protein characterization, bioassays, viral clearance studies and stability and lot release programs, we support clients throughout the biologic development cycle, from the establishment and characterization of cell banks through preclinical and clinical studies to marketed products. Whether clients need stand-alone services, a unique package of testing, or insourced support, our Biologics group can create a custom solution to suit their needs. Each year more than 20,000 biologic testing reports are sent each and over 200 licenses products are supported by our biologics testing solutions team.

About Charles River

Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 20,000 employees within 110 facilities in over 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of 86% of the drugs approved by the FDA in 2021.